{"nctId":"NCT01506882","briefTitle":"An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy","startDateStruct":{"date":"2011-12"},"conditions":["Epilepsy","Partial Onset Seizures"],"count":71,"armGroups":[{"label":"Levetiracetam 1000 mg/day to 2000 mg/day group","type":"EXPERIMENTAL","interventionNames":["Drug: Levetiracetam (LEV)"]},{"label":"Levetiracetam 3000 mg/day group","type":"EXPERIMENTAL","interventionNames":["Drug: Levetiracetam (LEV)"]}],"interventions":[{"name":"Levetiracetam (LEV)","otherNames":["Keppra","E Keppra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is male or female and aged â‰¥ 16 years at Visit 1\n* Subjects with newly or recently diagnosed Epilepsy having experienced unprovoked Partial Seizures (IA, IB, IC), that are classifiable according to the International League Against Epilepsy (ILAE) classification of Epileptic Seizures\n* Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year prior to Visit 1, of which, at least 1 unprovoked seizure occurred in the 3 months prior to Visit 1\n* Minimum body weight of 40 kg at Visit 1\n\nExclusion Criteria:\n\n* Subject has a history or presence of seizure types other than partial (IA, IB, IC)\n* Subject has an experience of any type of brain surgery in the consecutive 2 years prior to Visit 1\n* Subject has a history or presence of known Pseudo-Seizures\n* Subject has been treated for Epilepsy with any Antiepileptic Drug (AED) within the 6 months prior to Visit 1. However, acute and sub-acute seizure treatments are accepted for a maximum use of 2 weeks, if the treatments are stopped for the week prior to Visit 1\n* Subject has a known clinically significant acute or chronic illness, such as but not restricted to: cardiac, renal, hepatic dysfunction, endocrinological, or psychiatric illness, and that may impair reliable participation in the study or necessitate the use of medication not allowed by the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period","description":"A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:\n\n* A documented seizure during 6 consecutive months of the Evaluation Analysis Period\n* Subject discontinued the study prematurely during the Evaluation Analysis Period\n* Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period","description":"Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period","description":"A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:\n\n* A documented seizure during 6 consecutive months of the Evaluation Analysis Period\n* Subject discontinued the study prematurely during the Evaluation Analysis Period\n* Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period","description":"Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group","description":"Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.\n\nThe Median time to first seizure will be estimated from the Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group","description":"Median time to withdrawal will be estimated from the Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group","description":"Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.\n\nThe Median time to first seizure will be estimated from the Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group","description":"Median time to withdrawal will be estimated from the Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":61},"commonTop":["Nasopharyngitis","Somnolence","Malaise","Headache","Diarrhoea"]}}}